-The Times of India "We are sitting on a plastic time bomb," the Supreme Court said on Wednesday after the Central Pollution Control Board (CPCB) informed it that India generates 56 lakhtonnes of plastic waste annually, with Delhi accounting for a staggering 689.5 tonnes a day. "Total plastic waste which is collected and recycled in the country is estimated to be 9,205 tonnes per day (approximately 60% of total plastic waste) and...

-The Hindu chennai: Private non-minority unaided schools in the city will, hereafter, have to follow a streamlined admission procedure for intake of students under the 25 per cent quota mandated by the Right of Children to Free and Compulsory Education Act, 2009. A government order (G.O.) issued by the school education department on Monday prescribes not just a common schedule for issue of application forms and declaration of admission results, but also...

-The Indian Express chennai: The fate of Sterlite Industries, and that of thousands of people of coastal Tuticorin, now depends on the south bench of the National Green Tribunal, which is hearing the company's petition against its closure ordered by the Tamil Nadu Pollution Control Board (TNPCB). The biggest copper smelting unit in the country, part of the Vedanta Group, moved the tribunal after the TNPCB ordered closure of the plant following...

-The Business Standard Patients' lobbies cheer ruling on anti-cancer drug Glivec, as affordability and access to life-saving drugs get a leg-up Though the India office here of Swiss pharma giant Novartis wore a gloomy look following the Supreme Court rejection of its Glivec patent application, Indian pharmaceutical companies and patients' associations are in celebration mood. D G Shah, secretary general, The Indian Pharmaceutical Alliance (IPA), comprising leading research-based Indian pharma companies, said,...

-Live Mint SC rejects Novartis's patent plea for Glivec, says it does not meet any standard of novelty or inventiveness In a landmark judgement, India's apex court rejected Swiss drug maker Novartis AG's legal challenge aimed at securing a patent for blockbuster anti-cancer drug imatinib mesylate, branded Glivec in the country. The verdict, which is seen as a setback to multinational pharmaceutical companies operating in India, may influence a rash of pending disputes...